☰

Ravikiran Raju, Ph.D. - Publications

Affiliations: 
2012 Biological Sciences in Public Health Harvard University, Cambridge, MA, United States 
Area:
Molecular Biology, Microbiology Biology
Tree Info Similar researchers PubMed Report error

9 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2017 Lehmann J, Cheng TY, Aggarwal A, Park AS, Zeiler E, Raju RM, Akopian T, Kandror O, Bach NC, Sacchettini JC, Moody DB, Rubin EJ, Sieber SA. An antibacterial β-lactone kills Mycobacterium tuberculosis by infiltrating mycolic acid biosynthesis. Angewandte Chemie (International Ed. in English). PMID 29067779 DOI: 10.1002/Anie.201709365  0.446
2016 Marakalala MJ, Raju RM, Sharma K, Zhang YJ, Eugenin EA, Prideaux B, Daudelin IB, Chen PY, Booty MG, Kim JH, Eum SY, Via LE, Behar SM, Barry CE, Mann M, et al. Inflammatory signaling in human tuberculosis granulomas is spatially organized. Nature Medicine. PMID 27043495 DOI: 10.1038/Nm.4073  0.477
2016 Raju RM, Raju SM, Zhao Y, Rubin EJ. Leveraging Advances in Tuberculosis Diagnosis and Treatment to Address Nontuberculous Mycobacterial Disease. Emerging Infectious Diseases. 22: 365-9. PMID 26886068 DOI: 10.3201/Eid2203.151643  0.438
2015 Moreira W, Ngan GJ, Low JL, Poulsen A, Chia BC, Ang MJ, Yap A, Fulwood J, Lakshmanan U, Lim J, Khoo AY, Flotow H, Hill J, Raju RM, Rubin EJ, et al. Target mechanism-based whole-cell screening identifies bortezomib as an inhibitor of caseinolytic protease in mycobacteria. Mbio. 6: e00253-15. PMID 25944857 DOI: 10.1128/Mbio.00253-15  0.407
2014 Raju RM, Jedrychowski MP, Wei JR, Pinkham JT, Park AS, O'Brien K, Rehren G, Schnappinger D, Gygi SP, Rubin EJ. Post-translational regulation via Clp protease is critical for survival of Mycobacterium tuberculosis. Plos Pathogens. 10: e1003994. PMID 24603869 DOI: 10.1371/Journal.Ppat.1003994  0.43
2012 Raju RM, Goldberg AL, Rubin EJ. Bacterial proteolytic complexes as therapeutic targets. Nature Reviews. Drug Discovery. 11: 777-89. PMID 23023677 DOI: 10.1038/Nrd3846  0.411
2012 Raju RM, Unnikrishnan M, Rubin DH, Krishnamoorthy V, Kandror O, Akopian TN, Goldberg AL, Rubin EJ. Mycobacterium tuberculosis ClpP1 and ClpP2 function together in protein degradation and are required for viability in vitro and during infection. Plos Pathogens. 8: e1002511. PMID 22359499 DOI: 10.1371/Journal.Ppat.1002511  0.463
2012 Akopian T, Kandror O, Raju RM, Unnikrishnan M, Rubin EJ, Goldberg AL. The active ClpP protease from M. tuberculosis is a complex composed of a heptameric ClpP1 and a ClpP2 ring. The Embo Journal. 31: 1529-41. PMID 22286948 DOI: 10.1038/Emboj.2012.5  0.415
2012 La Rosa V, Poce G, Canseco JO, Buroni S, Pasca MR, Biava M, Raju RM, Porretta GC, Alfonso S, Battilocchio C, Javid B, Sorrentino F, Ioerger TR, Sacchettini JC, Manetti F, et al. MmpL3 is the cellular target of the antitubercular pyrrole derivative BM212. Antimicrobial Agents and Chemotherapy. 56: 324-31. PMID 22024828 DOI: 10.1128/Aac.05270-11  0.443
Show low-probability matches.